A Message from the IRIS Program IRIS Program Outlook June 2022

The IRIS Program is committed to producing assessments in a timely and transparent manner. Table 1 describes assessments that are currently in development and their projected public release dates. The IRIS Program is providing this information so that stakeholders are aware of upcoming assessment products, and to allow the public and research community an opportunity to communicate relevant research to EPA. When made public, the documents listed in Table 1 can be found at Regulations.gov in the IRIS public comment dockets. Docket numbers are listed on the IRIS website here: https://iris.epa.gov/Dockets/. While IRIS assessments are not associated with proposed rulemaking, Regulations.gov serves as both an internal portal to facilitate public comment and as a document repository for Federal government agencies.

Projected dates are based on factors such as the 1) scope of the assessment (e.g., size and complexity of a chemical's evidence base)ⁱ and 2) resource availability. Nearer-term activities are estimated using current Fiscal Year (FY) and Quarter. Long-term milestones are projected only for the FY due to the increased uncertainty of projecting timelines at the Quarter level. While projected dates reflect the IRIS Program's best estimate at this time based on available information, they are subject to change. Changes to estimated dates typically result from additional time needed to address the scientific challenges unique to each chemical assessment, new data, or respond to internal, public, and/or peer review comments, in addition to current EPA priorities and the availability of staff with the appropriate expertise to address those challenges. The IRIS Program Outlook is updated at least three times each calendar year (February, June, October). Table 1 includes the addition of cobalt (inhalation, cancer), which was added to address an Agency priority.

Additional information regarding other pertinent products relating to IRIS assessments and IRIS Program activities is included in Table 2. For questions regarding the IRIS Program activities, visit the <u>Contact Us</u> page on the EPA Website. For press inquiries, visit EPA's Office of Public Affairs website.

ⁱ The scope of IRIS assessments is generally discussed in the IRIS Assessment Plan (IAP). Information regarding size of the evidence base and expected key areas of scientific complexity is available in these documents. For information on how IAPs are developed, please see the IRIS Handbook: https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=350086.

Table 1. IRIS Assessment Products/Activities – June 2022

Assessment	Public Product(s)/Activity	Projected Date
Arsenic, Inorganic	Systematic Review Protocol	Released on May 28, 2019 for a 30-day public
		comment period until June 27, 2019.
		NAS review meeting July 16, 2019.
	Public Comment Draft	FY23 Q2
	External Peer Review	FY23
Chloroform (Inhalation) ¹	IRIS Assessment Plan	Released on September 18, 2017 for a 30-day public
		comment period until October 18, 2017.
		Public Science Meeting on September 27, 2017.
	Systematic Review Protocol	Released on January 31, 2018 for a 30-day public
	Public Comment Draft	comment period until March 2, 2018. FY23 Q1
	r ablic comment brait	1123 Q1
	External Peer Review	FY23 Q2
<u>Chromium VI</u>	Systematic Review Protocol	Released on March 15, 2019 for a 45-day public
		comment period until April 29, 2019.
		Public Science Meeting on April 24, 2019.
	Public Comment Draft	FY23 Q1
	External Peer Review	FY23 Q1
Cobalt and Cobalt Compounds (Inhalation, Cancer) ²	IRIS Assessment Plan	FY23 Q1
(innalation, Cancer) ²	Systematic Review Protocol	FY23 Q1
	Public Comment Draft	TBD
	External Peer Review	TBD
Ethylbenzene ^{1, 3}	IRIS Assessment Plan	Released on September 18, 2017 for a 30-day public
		comment period until October 18, 2017.
		Public Science Meeting on September 27, 2017.
	Systematic Review Protocol	FY23 Q1

Assessment	Public Product(s)/Activity	Projected Date
	Public Comment Draft	TBD
	External Peer Review	TBD
Formaldehyde ¹	Public Comment Draft	Released April 14, 2022 for a 60-day public comment period until June 13, 2022
	External Peer Review	See the National Academies of Sciences, Engineering, and Medicine (NASEM) website
Inorganic Mercury salts	IRIS Assessment Plan	Released on October 8, 2019 for a 30-day public comment period until November 7, 2019.
		Public science meeting on December 5, 2019
	Systematic Review Protocol	Released on March 11, 2021 for a 30-day public comment period until April 12, 2021.
	Public Comment Draft	FY23
	External Peer Review	FY23
Methylmercury	IRIS Assessment Plan	Released on April 4, 2019 for a 30-day public comment period until May 6, 2019.
	Systematic Review Protocol	Public Science Meeting on May 15, 2019 Released on May 28, 2020 for a 45-day public
	Public Comment Draft	comment period until July 13, 2020. FY23
	External Peer Review	FY24
Naphthalene ^{1,3}	IRIS Assessment Plan	Released on July 5, 2018 for a 30-day public comment period until August 6, 2018; extended until September 5, 2018.
		Public Science meeting originally scheduled for August 23, 2018 held November 9, 2021.
	Systematic Review Protocol	FY23 Q1
	Public Comment Draft	TBD
	External Peer Review	TBD

Assessment	Public Product(s)/Activity	Projected Date	
Perfluorobutanoic Acid (PFBA) ⁴	Systematic Review Protocol	Released on November 8, 2019 for a 45-day	
		comment period until December 23, 2019.	
	Public Comment Draft	Released on August 23, 2021 for a 60-day public	
		comment period until October 22, 2021; extended	
		until November 8, 2021.	
	External Peer Review	Public External Peer Review Meeting: February 22-	
		23, 2022 Peer Review Report: June 2022	
		Teer neview Report. June 2022	
	Final	FY23 Q1	
Perfluorodecanoic Acid (PFDA) ⁴	Systematic Review Protocol	Released on November 8, 2019 for a 45-day public	
		comment period until December 23, 2019.	
	Public Comment Draft	FY23 Q1	
	External Peer Review	FY23 Q2	
Perfluorohexanoic acid (PFHxA) ⁴	Systematic Review Protocol	Released on November 8, 2019 for a 45-day public	
		comment period until December 23, 2019.	
	Public Comment Draft	Released on February 2, 2022 for a 60-day public comment period until April 4, 2022.	
	External Peer Review	Public External Peer Review Meeting: May 16-17,	
		2022	
		Peer Review Report: expected FY22 Q4	
	Final	FY23 Q1	
Perfluorohexanesulfonic Acid	Systematic Review Protocol	Released on November 8, 2019 for a 45-day public	
(PFHxS) ⁴		comment period until December 23, 2019.	
	Public Comment Draft	FY23 Q2	
	External Peer Review	FY23 Q2	
Perfluorononanoic Acid (PFNA) ⁴	Systematic Review Protocol	Released on November 8, 2019 for a 45-day public	
		comment period until December 23, 2019.	
	Public Comment Draft	FY23 Q3	
	External Peer Review	FY23 Q3	
Polychlorinated Biphenyls	Systematic Review Protocol	Released on December 19, 2019 for a 30-day public	
(PCBs; Oral, Noncancer)		comment period until January 21, 2020.	
	Public Comment Draft	FY24	

Assessment	Public Product(s)/Activity	Projected Date	
	External Peer Review	FY25	
<u>Uranium</u> ^{1,3}	IRIS Assessment Plan	Released on January 31, 2018 for a 30-day public comment period until March 2, 2018.	
		Public Science Meeting on March 22, 2018	
	Systematic Review Protocol	FY23 Q1	
	Public Comment Draft	TBD	
	External Peer Review	TBD	
Vanadium and Compounds (Oral)	IRIS Assessment Plan	Released on July 24, 2020 for a 30-day comment period until August 24, 2020. Extended until September 23, 2020.	
		Public Science Meeting on August 19, 2020	
	Systematic Review Protocol	Released on April 26, 2021 for a 30-day public comment period until May 26, 2021.	
	Public Comment Draft	FY24	
	External Peer Review	FY24	
Vanadium and Compounds (Inhalation) ³	IRIS Assessment Plan	Released on May 28, 2021 for a 30-day public comment period until June 28, 2021. Public Science Meeting on July 14, 2021.	
	Systematic Review Protocol	FY23 Q1	
	Public Comment Draft	TBD	
	External Peer Review	TBD	

¹The chloroform, ethylbenzene, formaldehyde, naphthalene, and uranium IRIS assessments were suspended in April 2019 due to realignment of Agency priorities, see April 2019 IRIS Program Outlook here:

https://cfpub.epa.gov/ncea/iris drafts/recordisplay.cfm?deid=350410. Chloroform was later identified as a priority; see February 2020 IRIS Program Outlook, here: https://www.epa.gov/sites/default/files/2020-02/documents/iris program outlook feb2020.pdf. Formaldehyde was also later identified as a priority, while naphthalene, ethylbenzene, and uranium were nominated in FY21 and are currently in progress; see June 2021 IRIS Program Outlooks here: https://www.epa.gov/system/files/documents/2021-07/iris-program-outlook-june-2021.pdf.

²Cobalt and Cobalt Compounds (inhalation, cancer) was added to address an Agency priority.

³The IRIS Program is currently revising the ORD Staff Handbook for Developing IRIS Assessments ("IRIS Handbook") following external peer review by the National Academies of Sciences, Engineering, and Medicine (NASEM), which impacts the schedule of systematic

review protocol development for several assessments (ethylbenzene, naphthalene, uranium, vanadium and compounds (inhalation)). Following the systematic review protocol release, subsequent projected milestone dates (public comment and peer review) will be updated and provided in the next IRIS Program Outlook update.

⁴The five per- and polyfluoroalkyl Substances (PFAS) assessments are being developed according to the scope and methods outlined in the publicly posted systematic review protocol (https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=345065) and build upon several other PFAS assessments that have already been developed. These assessments represent only one component of the broader https://www.epa.gov/pfas/pfas-strategic-roadmap-epas-commitments-action-2021-2024.

Table 2. Upcoming IRIS Assessment support products and activities

Product or Activity	Next Anticipated Public Step(s)	Projected Date			
ORD Staff Handbook for Developing IRIS Assessments ("IRIS Handbook")	Final	FY23 Q1			
Cobalt and Cobalt Compounds (Preliminary Assessment Materials)	Public Meeting	FY23 Q1			
Peer Review Activities					
<u>PFHxA</u>	Peer Review Report	FY22 Q4			
<u>Formaldehyde</u>	Public External Peer Review Meeting	FY22 Q4			